Table 3.
OR for CR after electrochemotherapy
| Variable | CR (%) | Univariate analysis | Multivariate analysis | 1-year LPFS % | 95 % CI | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | 95 % CI | P | OR | 95 % CI | P | HR | 95 % CI | P | ||||
| Size | ||||||||||||
| <3 cm (n = 55) | 80.3 | 1.966 | 1.432–2.699 | <0.001 | 7.22 | 3.35–15.57 | <0.001 | 97.4 | 92.6–100 | 5.88 | 1.59–21.67 | 0.008 |
| ≥3 cm (n = 58) | 46.1 | 75.6 | 63.9–89.4 | |||||||||
| Ulceration | ||||||||||||
| No (n = 72) | 73.7 | 1.285 | 1.035–1.595 | 0.008 | 1.59 | 0.74–3.41 | 0.234 | 85.6 | 76.5–95.8 | 1.21 | 0.44–3.30 | 0.712 |
| Yes (n = 41) | 55.7 | 87.3 | 77.3–98.6 | |||||||||
| Receptor status | ||||||||||||
| ER positive (n = 65) | 77.2 | 1.590 | 1.149–2.199 | 0.006 | 2.45 | 1.19–5.07 | 0.016 | 84.8 | 75.4–95.3 | 0.85 | 0.37–3.33 | 0.852 |
| ER negative (n = 48) | 59.8 | 88.8 | 80.1–98.6 | |||||||||
| Ki-67 | ||||||||||||
| <14 % (n = 58) | 79.5 | 1.641 | 1.175–2.293 | <0.001 | 2.38 | 1.12–5.07 | 0.024 | 90.2 | 82.2–98.9 | 0.85 | 0.41–3.29 | 0.786 |
| >14 % (n = 55) | 58.0 | 80.7 | 69.0–94.5 | |||||||||
| Visceral metastases | ||||||||||||
| No (n = 67) | 80.5 | 1.783 | 1.364–2.330 | <0.001 | 3.60 | 1.66–7.79 | 0.001 | 86.5 | 77.4–96.7 | 1.98 | 0.72–5.50 | 0.185 |
| Yes (n = 46) | 55.0 | 86.0 | 76.0–97.3 | |||||||||
CR complete response, OR odds ratio, CI confidence interval, LPFS local progression-free survival, HR hazard ratio, ER estrogen receptor